Effect of recombinantly-derived bovine somatotropin on reproductive performance of dairy cattle

Data from 814 cows involved in five separate full lactation studies were used to assess the effect of recombinantly-derived methionyl bovine somatotropin (sometribove) on reproductive performance. Data were separated by parity (first and second or greater), route of administration (intramuscular: i.m. or subcutaneous: s.c.), length of breeding period (number of days in milk), and level of production (high vs low). Through 305 days in milk, pregnancy rates were reduced 18% in primiparous, sometribove-treated (i.m.) cows but were not significantly affected in multiparous cows. No differences were noted in either parity group when sometribove was administered subcutaneously. The level of production was more often found to be a significant factor affecting reproductive parameters than was sometribove administration. In general, length of the breeding period and level of milk production had a greater influence on reproductive performance than treatment with sometribove.